Post Archive by Year

After 100 years of use and billions of vaccinations, the world's deadliest infectious disease vaccine may soon be enhanced to meet the needs in 2025.
In a press release published on February 26, 2025, IAVI and Biofabri, a subsidiary of Zendal, announced that the first doses of tuberculosis MTBVAC vaccine candidate had been administered in the IMAGINE phase 2 clinical trial in Paarl, South Africa.

A recent study identified two proven, easy-to-implement tactics to increase vaccine uptake: Communicating doctor's or pharmacists' endorsements and delivering trusted vaccine information before an appointment. 
This University of Virginia School of Medicine study published by Open Forum Infectious Diseases concluded that strategies to engage older adult patients in vaccine decision-making increased rsv vaccination rates and patient-reported willingness to get vaccinated.

Numerous health agencies have repeatedly stated that getting the rotavirus vaccine is the best way to protect against this 'stomach' disease. Rotavirus is the leading global cause of severe dehydrating diarrhea in children.
A recent study supports that recommendation, finding a sustained and substantial decline in rotavirus-coded acute gastroenteritis (AGE) hospitalizations in children and adolescents 13 years after introducing the rotavirus vaccine.

The current dengue outbreak in Puerto Rico is the first since 2013, marking an unusually long gap between outbreaks. In 2025, residents and about 5 million visitors to this U.S. territory will continue to be at risk for this mosquito-transmitted disease.

While health agencies have issued travel alerts regarding France's Department of La Réunion Chikungunya outbreak for years, cases have spiked substantially since early 2025.
As of February 18, 2025, and since August 23, 2024, ARS Reunion confirmed 1,069 indigenous (local) cases recorded, including 927 since January 1, 2025.
The municipalities of Étang-Salé and Le Tampon have the most Chikungunya virus (CHIKV) cases, with 228 and 169 cases, respectively.

While the Yellow fever vaccine has been found highly effective when administered as a single dose, researchers have continued to examine the minimum dose requirements for seroconversion.
These researchers say the potential advantages of offering fractional doses are increased vaccinations and reduced under-vaccination, which have become a measurable health concern in the Region of the Americas over the past few years.
For example, 61 human cases of yellow fever were confirmed in the Region of the Americas in 2024, of which 30 were fatal (case fatality ratio, 50%).